WallStSmart
AQST

Aquestive Therapeutics Inc

NASDAQ: AQST · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$4.10
+1.23% today

Updated 2026-04-30

Market cap
$497.94M
P/E ratio
P/S ratio
11.18x
EPS (TTM)
$-0.78
Dividend yield
52W range
$2 – $8
Volume
1.7M

Aquestive Therapeutics Inc (AQST) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-65.4%
Last 4 quarters
Revenue YoY growth
+9.7%
Most recent quarter
EPS YoY growth
-61.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+2.1%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+3.4%
2026-03-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-04$-0.26-100.0%$4.12$4.26+3.4%
2025-11-05$-0.14+0.0%$6.08$6.13+0.8%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.13$-0.26-100.0%$13.02M+9.7%
2025-09-30$-0.14$-0.14+0.0%$12.81M-5.4%
2025-06-30$-0.17$-0.14+17.6%$10.00M-50.2%
2025-03-31$-0.08$-0.22-179.4%$8.72M-27.7%
2024-12-31$-0.13$-0.16-21.3%$11.87M-10.1%
2024-09-30$-0.13$-0.13+0.0%$13.54M+4.2%
2024-06-30$-0.12$-0.03+75.0%$20.10M+51.8%
2024-03-31$-0.08$-0.17-112.5%$12.05M
2023-12-31$-0.08$-0.11-37.5%$13.21M
2023-09-30$-0.11$-0.03+72.7%$13.00M
2023-06-30$-0.12$-0.10+16.7%$13.24M

Frequently asked questions

Has Aquestive Therapeutics Inc beaten earnings estimates?
Aquestive Therapeutics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -65.4% over the last 4 quarters.
How does AQST stock react to earnings?
AQST stock has moved an average of +2.1% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Aquestive Therapeutics Inc's revenue growth rate?
Aquestive Therapeutics Inc reported year-over-year revenue growth of +9.7% in its most recent quarter, with EPS growing -61.8% year-over-year.